Yes, other cellular mechanisms like the activation of alternative signaling pathways or the expression of drug efflux pumps can contribute to drug target alteration. Activation of the PI3K/AKT/mTOR pathway can bypass the inhibited target, allowing cancer cells to continue proliferating. Similarly, drug efflux pumps can reduce the intracellular concentration of the drug, diminishing its effectiveness.
